What People Report About BPC-157 — Self-Reported Community Data
BPC-157 is a synthetic compound derived from a protein found in human gastric juice. Based on self-reported experience logs shared on Narrated, it is most commonly logged for injury recovery, followed by joint health and gut healing. Contributors generally rated their outcomes positively. BPC-157 is FDA Category 2 in the US, banned by WADA since 2022, and not approved for human use.
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a pentadecapeptide — a chain of 15 amino acids. It was first identified in human gastric juice and has been studied primarily in animal models for tissue repair, inflammation, and wound healing. Human clinical trial data remains extremely limited as of March 2026.
BPC-157 is classified as a research compound. It is not approved by the FDA for human therapeutic use and was moved to FDA Category 2 in September 2023, restricting compounding pharmacy production.
What is the regulatory status of BPC-157?
As of March 2026:
- United States: FDA Category 2. Not approved for human use. Compounding pharmacies are restricted from producing it under current rules. No formal reclassification has occurred despite public announcements.
- United Kingdom: Not a licensed medicine. Available as a research chemical.
- WADA: Banned since January 2022 under the category of peptide hormones and growth factors. Athletes subject to anti-doping testing should be aware of this status.
What do people report when using BPC-157?
Based on self-reported experience logs shared on Narrated:
| Most common reported goal | Injury recovery |
|---|---|
| Second most common goal | Joint health |
| Third most common goal | Gut healing |
| Would run again | Majority of contributors |
| Neutral | A smaller proportion |
| Would not run again | A small minority |
The most commonly reported protocol: 250mcg/day subcutaneous injection, 4-8 week cycles, morning dosing. This reflects what people reported — not a dosage recommendation.
What are the reported side effects of BPC-157?
From self-reported logs on Narrated:
| None reported | Most common response |
|---|---|
| Injection site irritation | Commonly reported |
| Mild nausea (first week) | Moderately reported |
| Fatigue | Occasionally reported |
| Other | Rarely reported |
Self-reported side effect data has inherent limitations. People may not report mild effects, and the data reflects short-term cycles (typically 4-8 weeks).
What does the research say about BPC-157?
BPC-157 has been studied extensively in animal models, with published research on tendon healing, gut mucosal protection, wound healing, and neuroprotection. However, human clinical trials are extremely limited.
Key research context:
- Hundreds of animal studies published since the 1990s
- Mechanism of action involves angiogenesis, nitric oxide signaling, and growth factor modulation
- No completed Phase III human clinical trials as of March 2026
- Research depth rating on Narrated: Moderate
Is this medical advice?
No. Narrated aggregates self-reported community data. We present what people reported, the regulatory status, and the research context. We do not recommend, rank, or advise the use of any compound. Self-reported experiences are signal — not clinical evidence. Always consult a healthcare professional before making health decisions.